modelN02CC04

Diagram of N02CC04

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:Rizatriptan
ATC code:N02CC04
route:oral
compartments:1
dosage:10mg
volume of distribution:140L
clearance:41L/h
other parameters in model implementation

Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist (triptan class) used in the acute treatment of migraine attacks with or without aura in adults. It is approved and widely used today for this indication.

Pharmacokinetics

Healthy adult subjects, single-dose pharmacokinetics after oral administration.

References

  1. Tellone, V, et al., & Wedemeyer, RS (2020). A novel rizatriptan oral gel formulation: Bioavailability and bioequivalence. International journal of clinical pharmacology and therapeutics 58(10) 583–594. DOI:10.5414/CP203652 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32716291

  2. Fraser, IP, et al., & Winner, P (2012). Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. Headache 52(4) 625–635. DOI:10.1111/j.1526-4610.2011.02069.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/22289113

  3. Eiland, LS, & Hunt, MO (2010). The use of triptans for pediatric migraines. Paediatric drugs 12(6) 379–389. DOI:10.2165/11532860-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21028917

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)